Mediterr J Rheumatol 2023;34(3):367-71
Tofacitinib in Refractory Scleritis: A Case Series
Authors Information

1Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, Odisha, India

2Department of Ophthalmology, S.C.B Medical College, Cuttack, Odisha, India

S Dey, R Sarkar, A Pradhan, P Padhan, D Maikap

  1. Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol 1976;60:163-91.
  2. Cunningham ET Jr, McCluskey P, Pavesio C, Wakefield D, Zierhut M. Scleritis. Ocul Immunol Inflamm 2016;24(1):2-5.
  3. Sadhu S, Dutta Majumder P, Biswas J. Biological therapy in refractory cases of uveitis and scleritis: An analysis of 18 cases from a tertiary eye care center from South India. Indian J Ophthalmol 2020;68(9):1929-33.
  4. Sota J, Girolamo MM, Frediani B, Tosi GM, Cantarini L, Fabiani C. Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review. Ophthalmol Ther 2021;10(4):777-813.
  5. Wakefield D, Di Girolamo N, Thurau S, Wildner G, McCluskey P. Scleritis: immunopathogenesis and molecular basis for therapy. Prog Retin Eye Res 2013;35:44-62.
  6. Markus DV, Canelas Beer SM, Moca Trevisani VF. Tofacitinib as a Therapeutic Option in the Treatment of Refractory Scleritis: A Case Report. J Case Rep Stud 2021;9(1):104.
  7. Paley MA, Karacal H, Rao PK, Margolis TP, Miner JJ. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep 2018;13:53-55.
  8. Pyare R, Kaushik V, Dutta Majumder P, Biswas J. Tofacitinib in recalcitrant scleritis: First case report from India. Indian J Ophthalmol 2020;68:1988-90.
  9. Pyare R, Dutta Majumder P, Shah M, Kaushik V, Agarwal M, Biswas J. Tofacitinib in Scleritis: A Case Series. Ocul Immunol Inflamm 2022;1-7.
  10. Fabiani C, Sota J, Sainz-de-la-Maza M, Pelegrín L, Emmi G, Lopalco G, et al. New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy. Mediators Inflamm 2020;2020:8294560.